Madrigal Pharmaceuticals Inc.

Chief executives

Director election results

Annual meeting of June 16, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

• Julian Baker
  88.6%
• James M. Daly
  96.6%
• Daniel J. Brennan
  99.4%

Board connections

8 of this board's directors also sit on 20 other boards.

• ACADIA Pharmaceuticals Inc.
  via Felix Baker, James M. Daly and Julian Baker
• Incyte Corp.
  via Felix Baker, Jacqualyn A. Fouse and Julian Baker
• Kiniksa Pharmaceuticals International plc
  via Felix Baker, Julian Baker and Richard S. Levy
• Kodiak Sciences Inc
  via Felix Baker, Julian Baker and Richard S. Levy
• Prelude Therapeutics Incorporated
  via Felix Baker, Julian Baker and Paul A. Friedman
• vTv Therapeutics Inc.
  via Felix Baker, Julian Baker and Raymond Cheong
• BeOne Medicines Ltd.
  via Felix Baker and Julian Baker
• Bicycle Therapeutics plc
  via Felix Baker and Julian Baker
• DBV Technologies S.A.
  via Felix Baker and Julian Baker
• Denali Therapeutics Inc.
  via Felix Baker and Julian Baker
• Immunocore Holdings plc
  via Felix Baker and Julian Baker
• Kymera Therapeutics Inc.
  via Felix Baker and Julian Baker
• Neurogene Inc.
  via Felix Baker and Julian Baker
• Replimune Group Inc.
  via Felix Baker and Julian Baker
• TScan Therapeutics Inc.
  via Felix Baker and Julian Baker
• Agios Pharmaceuticals Inc.
  via Jacqualyn A. Fouse
• Cytokinetics Incorporated
  via James M. Daly
• Halozyme Therapeutics Inc.
  via James M. Daly
• Protara Therapeutics Inc.
  via Richard S. Levy
• Waters Corporation
  via Daniel J. Brennan

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months

$0

0 purchases by 0 insiders

Sold, last 12 months

$81,480,570

202 sales by 9 insiders

Sign in to write a review.